Table 1.
Clinical characteristics according to diabetic status before and after propensity matchinga
| Clinical parameters | Unmatched (complete) dataset | Propensity score-matched (1:1) datasetb | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Total | Diabetic (N=109) (%) | Nondiabetic (N=444)(%) |
p-value | Total | Diabetic (N=109) (%) | Non-diabetic (N=109)(%) |
p-value | ||
| Gender | Male | 293 | 63 (21.50) | 230 (78.50) | 0.285 | 125 | 63 (50.40) | 62 (49.60) | 1.000 |
| Female | 260 | 46 (17.69) | 214 (82.31) | 93 | 46 (49.46) | 47 (50.54) | |||
| Age | ≤60 years | 324 | 42 (12.96) | 282 (87.04) | <0.001 | 83 | 42 (50.60) | 41 (49.40) | 1.000 |
| >60 years | 229 | 67 (29.26) | 162 (70.74) | 135 | 67 (49.63) | 68 (50.37) | |||
| IPI | 0−2 | 381 | 67 (17.59) | 314 (82.41) | 0.065 | 138 | 67 (48.55) | 71 (51.45) | 0.673 |
| 3−5 | 172 | 42 (24.42) | 130 (75.58) | 80 | 42 (52.50) | 38 (47.50) | |||
| Stage | I−II | 209 | 38 (18.18) | 171 (81.82) | 0.510 | 77 | 38 (49.35) | 39 (50.65) | 1.000 |
| III−IV | 344 | 71 (20.64) | 273 (79.36) | 141 | 71 (50.35) | 70 (49.65) | |||
| ECOG PS | 0−1 | 471 | 87 (18.47) | 384 (81.53) | 0.097 | 180 | 87 (48.33) | 93 (51.67) | 0.372 |
| 2−4 | 82 | 22 (26.83) | 60 (73.17) | 38 | 22 (57.89) | 16 (42.11) | |||
| Extranodal site(s) | ≤1 | 403 | 78 (19.35) | 325 (80.65) | 0.720 | 159 | 78 (49.06) | 81 (50.94) | 0.761 |
| >1 | 150 | 31 (20.67) | 119 (79.33) | 59 | 31 (52.54) | 28 (47.46) | |||
| Hans classification | GCB | 211 | 37 (17.54) | 174 (82.46) | 0.324 | 71 | 37 (52.11) | 34 (47.89) | 0.773 |
| Non-GCB | 342 | 72 (21.05) | 270 (78.95) | 147 | 72 (48.98) | 75 (51.02) | |||
| Symptoms | No B symptoms | 342 | 64 (18.71) | 278 (81.29) | 0.509 | 132 | 64 (48.48) | 68 (51.52) | 0.678 |
| B symptoms | 211 | 45 (21.33) | 166 (78.67) | 86 | 45 (52.33) | 41 (47.67) | |||
| LDH | ≤ULN (271U/L) | 351 | 63 (17.95) | 288 (82.05) | 0.183 | 131 | 63 (48.09) | 68 (51.91) | 0.580 |
| >ULN (271U/L) | 202 | 46 (22.77) | 156 (77.23) | 87 | 46 (52.87) | 41 (47.13) | |||
| Albumin | <LLN (40U/L) | 332 | 69 (20.78) | 263 (79.22) | 0.448 | 128 | 69 (53.91) | 59 (46.09) | 0.216 |
| ≥LLN (40U/L) | 221 | 40 (18.10) | 181 (81.90) | 90 | 40 (44.44) | 50 (55.56) | |||
| Treatments | R-CHOP | 404 | 80 (19.80) | 324 (80.20) | 0.692 | 164 | 80 (48.78) | 84 (51.22) | 0.917 |
| DA-EPOCH+R | 118 | 21 (17.80) | 97 (82.20) | 40 | 21 (52.50) | 19 (47.50) | |||
| R-CHOP like regimens | 22 | 5 (22.73) | 17 (77.27) | 9 | 5 (55.56) | 4 (44.44) | |||
| R-mini CHOP | 9 | 3 (33.33) | 6 (66.67) | 5 | 3 (60.00) | 2 (40.00) | |||
| Response to therapyc | CR or PR | 392 | 70 (17.86) | 322 (82.14) | 0.314 | 147 | 70 (47.62) | 77 (52.38) | 0.643 |
| Non-CR or PR | 138 | 30 (21.74) | 108 (78.26) | 58 | 30 (51.72) | 28 (48.28) | |||
Notes: aThe tests used were the Chi-square test or the Fisher’s exact test. bPropensity score-matched (1:1, 109 pairs) analyses were performed with a small caliper of 0.1 for matching potential confounders including sex, age, stage, ECOG PS, extranodal site(s), Hans classification, symptoms and LDH level. cThe evaluation of treatment response was performed after 6−8 cycles of chemotherapies. Patients who died during the therapies were excluded, including 23 in unmatched dataset and 13 in propensity score-matched dataset.
Abbreviations: IPI, international prognostic index; ECOG, Eastern Cooperative Oncology Group; PS, performance status; GCB, germinal center B-cell; LDH, lactate dehydrogenase; ULN, upper limit of normal; LLN, lower limit of normal; R-CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; DA-EPOCH+R, dose-adjusted (etoposide, prednisone, vincristine, cyclophosphamide and doxorubicin) plus rituximab; R-mini CHOP, rituximab combined with low-dose CHOP; CR, complete remission; PR, partial remission.